Biotech Values

[Whalatane]

AMRN. Dew , re their balance sheet . I think they are about cash flow positive now ...since the Reduce It trial has ended and their R&D expenses will be far lower going forward.
Note
Cash balance: As of June 30, 2018, Amarin had a cash balance of $102.3 million.

Couple of key catalysts coming up
1) Believe they are presenting at the Cardio metabolic conference starting this week. It will be only previously released data but will generate some attention
2) AHA is Nov 10th ...where they will present details from their Reduce -It Outcome trial
3) NEJM publication of the Reduce -IT soon after AHA .

AMRN has not done a capital raise since R-IT results Sept 24 . Some speculation as to why not .
1) They have enough cash to go it alone ...maybe $80m remaining COH
2) Might consider buy out offers after full R-IT data release
3) May partner with a Big Pharma co re EU rights

Your friend JL has lead the charge on AMRN ....and has been right .

TG levels are the new LDL levels ... ( as in brown is the new black )

Kiwi